1334136-11-6

Basic information

• Product Name: (11aS)-7-methoxy-8-(3-(2-methoxy-5-(4-(6-(4-methoxyphenyl)-2-naphthoyl)piperazine-1-carbonyl)phenoxy)propoxy)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one
• CAS NO: 1334136-11-6
• Molecular Weight: 782.893
• Mol File: 1334136-11-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (11aS)-7-methoxy-8-(3-(2-methoxy-5-(4-(6-(4-methoxyphenyl)-2-naphthoyl)piperazine-1-carbonyl)phenoxy)propoxy)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (11aS)-7-methoxy-8-(3-(2-methoxy-5-(4-(6-(4-methoxyphenyl)-2-naphthoyl)piperazine-1-carbonyl)phenoxy)propoxy)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one(1334136-11-6)
• EPA Substance Registry System: (11aS)-7-methoxy-8-(3-(2-methoxy-5-(4-(6-(4-methoxyphenyl)-2-naphthoyl)piperazine-1-carbonyl)phenoxy)propoxy)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5(11aH)-one(1334136-11-6)

Safety Data

• Hazardous Substances Data: 1334136-11-6(Hazardous Substances Data)

Upstream product

• 289896-68-0 3-hydroxy-4-methoxybenzoyl chloride 
• 86471-14-9 ethyl 6-bromo-naphthalene-2-carboxylate 
• 5720-07-0 4-methoxyphenylboronic acid 
• 645-08-9 Isovanillic acid 
• 1334136-34-3 C₃₃H₃₃BrN₂O₅ 
• 1334137-43-7 C₃₀H₂₈N₂O₅ 
• 1334137-61-9 C₁₈H₁₃ClO₂ 
• 1334137-72-2 (3-hydroxy-4-methoxybenzoyl)-1-piperazine 
• 1334137-74-4 tert-butyl 4-(3-hydroxy-4-methoxybenzoyl)-1-piperazinecarboxylate 
• 1334138-60-1 C₅₀H₅₆N₄O₁₀S₂ 
• 1334137-82-4 ethyl 6-(4-methoxyphenyl)-2-naphthoate 
• 132292-17-2 6-(4-methoxyphenyl)-2-naphthoic acid 

Relevant articles and documents

Synthesis of aryl-substituted naphthalene-linked pyrrolobenzodiazepine conjugates as potential anticancer agents with apoptosis-inducing ability

A library of new aryl-substituted naphthalene C8-linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates with various linker architectures were designed, synthesized, and evaluated for their anticancer activity against a panel of 11 human cancer cell lines. All 32 conjugates show anticancer potential, with some of them exhibiting particularly high activity (0.01-0.19μM). Thermal denaturation studies showed effective DNA binding capacity relative to DC-81. In assays for biological activity relating to cell-cycle distribution, these PBD conjugates induce G0/G1-phase arrest and also cause an increase in the levels of p53 and caspase-9 proteins, followed by apoptotic cell death. One conjugate in particular is the most promising candidate of the series, with the potential to be selected for further studies, either alone or in combination with existing anticancer therapies. Getting into the groove: Pyrrolobenzodiazepine (PBD) conjugates showed an effective ability to bind DNA. They induce G0/G1-phase arrest, enhance the expression levels of p53 and caspase-9, and induce apoptosis. One conjugate stands out as particularly promising; it is a suitable candidate for further study, either alone or in combination with current anticancer therapies.